SofWave Medical Ltd. Company Analysis & Research
SofWave Medical is a developer and distributor of non-invasive aesthetic medical devices, offering ultrasound technology under the SUPERB brand for skin rejuvenation and wrinkle reduction, plus muscle toning technology under the Pure Impact brand. The company serves plastic surgeons, dermatologists, and aesthetic practitioners globally.
SofWave demonstrated exceptional growth momentum with 2025 revenue of $87.3-87.6 million, up approximately 46% year-over-year from $59.7 million in 2024. The company is evaluating a potential U.S. public offering and approved submission of a confidential Form F-1 Registration Statement to the SEC in January 2026.
Company Overview
Founded: 2015. Headquarters: Yokneam Illit, Israel. Revenue: $87.3-87.6M (2025E). Employees: 126. Market Cap: ~$460M. Ticker: SOFW (TASE).
Industry
Aesthetic Medical Devices / Non-Invasive Dermatology
Cyborg Score: 8/10 — Strong
High-growth aesthetic medical device company with proprietary ultrasound technology, strong market traction, and near-term U.S. expansion catalysts justifying premium valuation for growth-oriented investors.
SofWave exhibits strong fundamentals with 46% YoY revenue growth, expanding cash position, FDA-cleared flagship product, and leadership by industry veteran executives. Primary headwinds include valuation premium relative to peer benchmarks and execution risk on U.S. IPO transition.
Key Strategic Insights for SofWave Medical Ltd.
- Explosive growth acceleration: Q4 2025 revenue of $28.6-28.9M (+57% YoY) significantly outpaced full-year growth of 46%, signaling strengthening market demand and operational scaling
- U.S. market expansion: Confidential Form F-1 filing suggests imminent Nasdaq listing, unlocking access to larger institutional capital pools and enhanced brand recognition in primary aesthetic market
- Leadership pedigree: CEO Louis Scafuri and Chairman Dr. Shimon Eckhouse bring decades of medtech experience from Syneron Candela and Lumenis, reducing execution risk
- Regulatory footprint: FDA and CE clearance across multiple indications (facial lines, laxity, cellulite, acne scars) provides clinical validation and market credibility versus competitors
Recent Developments
- (January 2026) Form F-1 confidential submission approved for potential U.S. public offering to evaluate Nasdaq listing
- (January 2026) Q4 2025 preliminary results: revenue $28.6-28.9M (+57% YoY), full-year 2025 revenue $87.3-87.6M (+46% YoY)
- (January 2026) Cash position increased to $35.2M as of December 31, 2025
Competitors & Competitive Landscape
- Ulthera (Merz subsidiary) — Ultrasound technology for non-invasive skin lifting and tightening
- Lumenis — Laser and light-based aesthetic devices
- Cutera — Multi-platform aesthetic laser and RF systems
SofWave's primary competitor is U.S.-based Ulthera. Additional competitors in the aesthetic device space include Lumenis (laser/light-based), Cutera (platform), and Cynosure (energy-based systems). SofWave's proprietary SUPERB ultrasound technology and Pure Impact EMS module create differentiation, though competitive intensity is rising with new entrants in non-invasive aesthetics.
More Company Research
Lokum Deweloper S.A. Aurora Cannabis Aarti Drugs Limited Skellerup Holdings Limited Troax Group AB Sable Offshore Corp. Shanghai Industrial Holdings Limited NOK Corporation Align Technology, Inc. FPT Corporation Concordia Financial Group, Ltd. Halma plc D.R. Horton, Inc. Dubai Taxi Company MS Industrie AGFull Company Research Reports
Looking for a more in-depth analysis of SofWave Medical Ltd.? AskCyborg's Company Research section contains full AI-generated reports with detailed financials, strategic analysis, and Cyborg Score ratings. Browse the complete company research library or explore industry research reports.
AskCyborg provides AI-powered company research and analysis. Visit AskCyborg for full reports, Cyborg Score ratings, and analyst podcasts.